Post Menopausal Osteoporosis Market
DelveInsight's "Post Menopausal Osteoporosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Post Menopausal Osteoporosis, historical and forecasted epidemiology as well as the Post Menopausal Osteoporosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Post Menopausal Osteoporosis market report provides current treatment practices, emerging drugs, Post Menopausal Osteoporosis market share of the individual therapies, current and forecasted Post Menopausal Osteoporosis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Post Menopausal Osteoporosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Post Menopausal Osteoporosis market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Post Menopausal Osteoporosis Disease Understanding and Treatment Algorithm
Osteoporosis is a metabolic bone condition characterized by reduced bone mass and micro-architectural bone tissue degradation. The most common osteoporotic fractures are those of the proximal femur, vertebrae, and distal radius. The most common kind of osteoporosis is postmenopausal osteoporosis caused by oestrogen insufficiency. Because of the impact on all types of bone cells, estrogen shortage causes an increase in bone turnover. The imbalance in bone formation and resorption affects trabecular bone (loss of connection) as well as cortical bone (cortical thinning and porosity).
Bone density tests of the lumbar spine and proximal femur are used to diagnose osteoporosis. Diet, exercise, and quitting smoking are all preventive practices for better bone health. Improved understanding of the cellular basis of osteoporosis has resulted in the development of novel drugs targeting key pathways.
Post Menopausal Osteoporosis Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Post Menopausal Osteoporosis.
Post Menopausal Osteoporosis Treatment
It covers the details of conventional and current medical therapies available in the Post Menopausal Osteoporosis market for the treatment of the condition. It also provides Post Menopausal Osteoporosis treatment algorithms and guidelines in the United States, Europe, and Japan.
Post Menopausal Osteoporosis Epidemiology
The Post Menopausal Osteoporosis epidemiology section provides insights about the historical and current Post Menopausal Osteoporosis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Post Menopausal Osteoporosis market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Post Menopausal Osteoporosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
- In 2017, the overall diagnosed prevalent population of osteoporosis in the seven major markets was 28,097,783 cases. While the overall diagnosed prevalent population of osteoporosis in the United States was 6,380,754 cases in 2017, this figure is predicted to rise by 2030.
- Tian et al. conducted a study titled "Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men," in which the reported prevalence of osteoporosis in women was 9% in the United Kingdom, 15% in France and Germany, 16% in the United States, and 38% in Japan. The overall prevalence of osteoporosis was 9.65 percent for postmenopausal women and 8.08 percent for old men.
- In 2017, the total diagnosed osteoporosis prevalent population in EU5 was found to be maximum in Germany with 4,309,667 cases, followed by Italy with 3,840,703 cases. In the same year, France had the lowest number of diagnosed prevalent cases of osteoporosis with 2,786,944 cases.
- According to a poster presented by the American Association of Clinical Endocrinologists, women who have a hip fracture have a 12- to 20-percentage increase in mortality over the next two years. More than half of hip fracture survivors are unable to re-establish their independence. Each year, more than 2 million osteoporosis-related fractures occur in the United States, with women accounting for more than 70% of them. Vertebral fractures are prevalent in more than 20% of postmenopausal women.
- According to a Sessa study titled "Clinical guidelines for the prevention and treatment of osteoporosis from the Italian Society for Orthopaedics and Traumatology: preface," osteoporosis potentially affects about 5,000,000 people in Italy, with 80 percent of those affected being postmenopausal women.
Country Wise- Post Menopausal Osteoporosis Epidemiology
The epidemiology segment also provides the Post Menopausal Osteoporosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Post Menopausal Osteoporosis Drug Chapters
The drug chapter segment of the Post Menopausal Osteoporosis report encloses the detailed analysis of Post Menopausal Osteoporosis marketed drugs and late-stage (Phase-III and Phase-II) Post Menopausal Osteoporosis pipeline drugs. It also helps to understand the Post Menopausal Osteoporosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Post Menopausal Osteoporosis Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Post Menopausal Osteoporosis treatment.
Post Menopausal Osteoporosis Companies:
- Sandoz
- Haoma Medica
- Amgen Inc.
- Clonz Biotech
- Eli Lilly and Company,
- Enteris BioPharma
- Ligand Pharmaceuticals Incorporated.
- Merck & Co., Inc
- Outlook Therapeutics, Inc
- And Many Others
Post Menopausal Osteoporosis Therapies:
- Denosumab (GP2411)
- NaQuinate
- And Many Others
Post Menopausal Osteoporosis Market Outlook
The Post Menopausal Osteoporosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Post Menopausal Osteoporosis market trends by analyzing the impact of current Post Menopausal Osteoporosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Post Menopausal Osteoporosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Post Menopausal Osteoporosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Post Menopausal Osteoporosis market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Post Menopausal Osteoporosis market in 7MM.
The United States: Post Menopausal Osteoporosis Market Outlook
This section provides the total Post Menopausal Osteoporosis market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Post Menopausal Osteoporosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Post Menopausal Osteoporosis market size and market size by therapies in Japan is also mentioned.
Post Menopausal Osteoporosis Drugs Uptake
This section focuses on the rate of uptake of the potential Post Menopausal Osteoporosis drugs recently launched in the Post Menopausal Osteoporosis market or expected to get launched in the market during the study period 2019-2032. The analysis covers Post Menopausal Osteoporosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Post Menopausal Osteoporosis Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Post Menopausal Osteoporosis market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Post Menopausal Osteoporosis Pipeline Development Activities
The Post Menopausal Osteoporosis report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Post Menopausal Osteoporosis key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Post Menopausal Osteoporosis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Post Menopausal Osteoporosis emerging therapies.
Reimbursement Scenario in Post Menopausal Osteoporosis
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current Post Menopausal Osteoporosis market trends, we take KOLs and SMEs ' opinion working in the Post Menopausal Osteoporosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Post Menopausal Osteoporosis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Post Menopausal Osteoporosis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Post Menopausal Osteoporosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Post Menopausal Osteoporosis epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Post Menopausal Osteoporosis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Post Menopausal Osteoporosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Post Menopausal Osteoporosis market
Report Highlights
- In the coming years, the Post Menopausal Osteoporosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Post Menopausal Osteoporosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Post Menopausal Osteoporosis. The launch of emerging therapies will significantly impact the Post Menopausal Osteoporosis market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Post Menopausal Osteoporosis
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Post Menopausal Osteoporosis Report Insights
- Post Menopausal Osteoporosis Patient Population
- Therapeutic Approaches
- Post Menopausal Osteoporosis Pipeline Analysis
- Post Menopausal Osteoporosis Market Size and Trends
- Post Menopausal Osteoporosis Market Opportunities
- Impact of upcoming Post Menopausal Osteoporosis Therapies
Post Menopausal Osteoporosis Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Post Menopausal Osteoporosis Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Post Menopausal Osteoporosis Report Assessment
- Current Treatment Practices
- Unmet Needs
- Post Menopausal Osteoporosis Pipeline Product Profiles
- Post Menopausal Osteoporosis Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Post Menopausal Osteoporosis drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Post Menopausal Osteoporosis total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Post Menopausal Osteoporosis market size during the forecast period (2019-2032)?
- At what CAGR, the Post Menopausal Osteoporosis market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Post Menopausal Osteoporosis market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Post Menopausal Osteoporosis market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Post Menopausal Osteoporosis?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Post Menopausal Osteoporosis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Post Menopausal Osteoporosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Post Menopausal Osteoporosis?
- Out of all 7MM countries, which country would have the highest prevalent population of Post Menopausal Osteoporosis during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Post Menopausal Osteoporosis treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Post Menopausal Osteoporosis in the USA, Europe, and Japan?
- What are the Post Menopausal Osteoporosis marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Post Menopausal Osteoporosis?
- How many therapies are in-development by each company for Post Menopausal Osteoporosis treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Post Menopausal Osteoporosis treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Post Menopausal Osteoporosis therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Post Menopausal Osteoporosis and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Post Menopausal Osteoporosis?
- What are the global historical and forecasted market of Post Menopausal Osteoporosis?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Post Menopausal Osteoporosis market
- To understand the future market competition in the Post Menopausal Osteoporosis market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Post Menopausal Osteoporosis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Post Menopausal Osteoporosis market
- To understand the future market competition in the Post Menopausal Osteoporosis market
